Tuesday, August 9, 2016

Journal warns against unnecessary use of antioxidant supplements

journal warns against unnecessary use of antioxidant supplements -
The secular press and thousands of nutritional products warn of oxygen radicals, or oxidative stress and suggest taking so-called antioxidants to prevent or cure a disease. Professor Pietro Ghezzi at Brighton and Sussex Medical School and Professor Harald Schmidt from Maastricht University have analyzed the evidence behind this. The result is a clear warning :. Do not take these supplements unless an obvious gap is diagnosed by a health professional
Humans depend on oxygen to produce energy, but oxygen also has the potential to generate of said oxygen radicals, which can cause oxidative stress and disease. oxidative stress markers have been correlated with cardiovascular disease, cancer, diabetes and other conditions. Because of these associations, antioxidant supplements are taken by millions of people; However, none of antioxidants tested in randomized clinical trials have shown a benefit. On the contrary, some of them may cause damage. Indeed, oxygen radicals not only trigger the disease, but also perform many important functions in the body, as for the immune defense and the synthesis of hormones. Thus antioxidants will interfere with both molecules healthy and oxygen trigger diseases.
"Oxidative stress may be important in certain conditions and only in a small proportion of patients," said Professor Ghezzi. "It can be targeted in a totally different way, with targeted drugs only at the source of oxygen molecules that are triggers of the disease and allow only healthy," said Professor Schmidt. The journal is published on British Journal of Pharmacology .

A clinical trial to evaluate the safety of medicines palbociclib among African-American women with breast cancer

A clinical trial to evaluate the safety of medicines palbociclib among African-American women with breast cancer -

The first clinical trial to test a drug against cancer the newly approved specifically for African-American patients breast is now enroll in Georgetown Lombardi Comprehensive Cancer Center and soon begin five other institutions in Washington, DC, Maryland, Alabama and New Jersey.

Phase II study will assess the safety of palbociclib (Ibrance ®) African-American patients, including those who may have low blood cell counts because of "benign ethnic neutropenia." This condition is common in African Americans, but it is unclear whether it increases the risk of infection of a patient while taking palbociclib, said the study leader, Filipa Lynce, MD, a research physician at Georgetown Lombardi Comprehensive cancer Center.

the Food and Drug administration of the United States approved palbociclib in February 2016 for cancer HER2 + breast ER that propagated.

Because three quarters of 1,137 patients tested in previous clinical trials of palbociclib developed neutropenia (low white blood cell numbers) - including half of the patients who developed a more severe form of the disease. - FDA guidelines for the use palbociclib require the patient to have a normal blood cell count

This threshold requires the elimination of African American women who have "benign ethnic neutropenia ', or white blood cells in the blood below the normal to receive the drug.

leads the Lynce study explores the drug's safety in all African American women, knowing that some may have a benign ethnic neutropenia. "The assumption that African-American women with this common condition could not safely use this medication must be fully tested," said Lynce.

The study will enroll 35 patients with metastatic breast cancer at Georgetown Lombardi / MedStar Georgetown University Hospital (Washington, DC), MedStar WashingtonHospital Center (Washington, DC), MedStar Memorial Hospital Union (Baltimore, MD) andMedStar Good Samaritan Hospital (Baltimore, MD), the University of Alabama at BirminghamComprehensive cancer Center and cancer Center John Theurer Hackensack University medical Center (Hackensack, NJ).

All patients will receive palbociclib and letrozole (Femara). both agents are . pills that are taken once daily participants will be enrolled in the study for up to 13 months

the usual standard of care required to monitor and treat cancer -. Includes examinations, analysis and laboratory tests - will be conducted as part of the study and billed to the insurance of a patient. The main drug study palbociclib will be provided free for study but the second drug, letrozole, will also be charged for insurance.

Lynce applied and received a $ 0,000 grant from Pfizer, Inc., the developer of palbociclib to test the agent in African Americans.

I think this award shows how committed the company is to examine the safety of their products in the minority, "said Lynce." A staging area to the point of my research is to examine the safety and effectiveness of drugs used to treat breast cancer in populations that are not included in clinical trials.

Scientists reveal how tumor cells exploit function of mitochondria to support the proliferation of cancer

Scientists reveal how tumor cells exploit function of mitochondria to support the proliferation of cancer -
As the central cells, mitochondria are critical for every organization because of their role in energy production while also monitoring the survival, but the way they work in cancer is not fully known. This is particularly important because, in general, tumor cells proliferate more than normal tissue, and scientists have speculated that the mechanisms that maintain mitochondrial function are responsible for supporting the expansion of the tumor.
Now Wistar Institute's scientists have identified a specific network of proteins in the mitochondria of tumor cells which is essential for the maintenance of mitochondrial cleaning function, which not only allows the proliferation of tumor cells, but also their ability to move and invade distant organs. By understanding the actors involved, the Wistar scientists have been able to disable individual subunits within the network, greatly reducing the ability of cancer cells to grow and spread, suggesting an attractive new therapeutic target. The results were published in the journal PLoS Biology.
"This is an example of how tumors can quickly adapt to meet their own needs biosynthetic higher," said Dario C. Altieri, MD, president and CEO of the Wistar Institute, Director the Wistar Institute cancer Centre, Robert & Penny Fox distinguished Professor and lead author of the study. "mitochondria play a crucial role in the ability of a tumor to treat the energy to grow and spread to to identify the mechanisms of how tumors maintain mitochondrial function and operate to support the abnormal cell proliferation and metastasis can discover new therapeutic targets in a wide variety of cancers. "
previous studies have provided evidence that the ability to control the folding and stability of proteins, or proteostasis, the importance of reducing cellular stress. It has also been known that tumors hijack proteostasis mechanisms to their advantage, but how this happened in the mitochondria remained largely unknown. The network described by the Wistar scientists answered this question and confirmed its important role in tumor development. In particular, one of the components of this network - ClpP - was found universally overexpressed in primary human cancer and metastatic and is correlated with shortened survival of patients. In this single study, the scientists identified the overexpression of this subunit in breast, prostate, colon and lung, as well as melanoma and lymphoma.
"There is little interest in targeting pathways involved in mitochondrial function, and we have identified such a way that can provide a target" drugable "for a variety of cancers," said Seo Jae Ho, Ph.D., a postdoctoral fellow in the laboratory at Wistar Altieri and first author of the study. "Other studies have shown that it is possible to target mitochondrial proteins in preclinical models to disrupt the network, we identified in this study could stop key processes that lead to the progression of the tumor."

Monday, August 8, 2016

Complete Proscia $ 1M seed round funding to advance cancer diagnosis, the treatment

Complete Proscia $ 1M seed round funding to advance cancer diagnosis, the treatment -
Proscia Inc., a data provider of solutions for digital pathology, has today announced the completion of its $ 1M seed round of financing. Proscia Pathology Cloud Platform which is already helping hundreds of pathologists and researchers will use the proceeds to accelerate growth and to pursue the vision of the company to unlock ideas and accelerate the discovery toward understanding and treating cancer.
The financing was led by Emerald Development Managers, with the participation of Robin Hood Ventures, Venture Capital and TCP A-Level Capital. "Our team is very impressed with the Proscia team, their vision and ability to execute," said Neil Cohen development managers Emerald, "They have a compelling pipeline of pathology solutions which will undoubtedly improve the diagnosis and cancer treatment. "
The Baltimore company was founded in 2014 by technicians from Johns Hopkins University and other academic institutions. The Proscia software, which includes machine learning, computer vision and cloud computing, recognizes the histological patterns in whole slide images and quantifies tissue manner not possible with the naked eye and microscope. "Quantitative techniques allow digital images to increase the field of pathology in new ways," said Dr. Liron Pantanowitz, director of IT Pathology at the University of Pittsburgh Medical Center, "In the end, with these capabilities, digital pathology will allow more accurate diagnoses. "UPMC and Proscia expect soon announce a partnership co-development to bring new quantitative tools state-of-the-art in digital pathology.
"Precision Medicine in the fight against cancer saves lives and long-term health care costs," said David West, Jr., President and CEO of Proscia " as digital imaging did for radiology, our software will usher in a new era of computer assisted pathology accelerate the fight against deadly diseases. We are pleased and grateful for the support of our investors to help us achieve our vision. "

One study found that the high costs of health care for patients with chronic pain in Canada

One study found that the high costs of health care for patients with chronic pain in Canada -
The costs of patients who develop chronic post-surgical pain could go $ 2.5 million to $ 4.1 million per year in an Ontario hospital alone, according to a study pain management
in an article entitled, pain chronic post-surgical and persistent use of opioids after surgery :. the need for a service of transient pain, ON- published online July 6, 2016 pain management , a team led by Dr. Hance Clarke, Medical Director of the Research Unit on pain Toronto General Hospital (TGH), University Health Network (UHN), estimates that nearly 15 percent of patients with complex post-operative pain develop moderate to severe chronic post-surgical pain, have significant disability and continue to use opioids to relieve long-term pain.
more, these patients consume 0 percent of the resources related to the pain of health, such as the repeated pain of visits to doctors, prolonged length of stay stays, and are at risk of rehospitalization . On average, patients with chronic pain are five to seven days longer in the hospital for the same condition than patients who do not suffer from chronic pain.
"We must break the cycle of pain before it becomes chronic. It is much more difficult to treat someone when pain is anchored, and the window of opportunity is lost," says lead author Dr. Hance Clarke, who is also director of the transition pain service in the department of anesthesia and pain management at Toronto General Hospital (TGH) and clinical researcher at the Institute Toronto General research. he added that after about six months, post-surgical pain can turn into chronic pain, it is important to intervene before it happens. in general, 50 percent to 70 percent patients after major surgery are discharged from the hospital with a prescription of opioids.
in this study, Dr. Clarke outlines the expected annual total costs associated with TGH surgical patients who develop moderate to severe post-surgical chronic pain, disability, pain, and the use of persistent opioid. Five percent of all surgeries to TGH cause of new cases of chronic post-surgical pain, says Dr Clarke. This, in addition to about 13 percent of surgical patients suffering from TGH previous chronic pain, which worsens after surgery, adds to the cost of annual chronic pain ranging from $ 2.5 million for a possible $ 4.1 million to the Ontario health care system of a hospital. These estimates are calculated using data obtained from the latest studies on the use of health care that estimate the health care costs for patients with chronic pain in Ontario to be approximately $ 5,000 per year for a patient.
"Pain is an epidemic, and the costs to the health care system and for patients are enormous," says Dr Clarke. He noted that chronic pain costs the Canadian health care system between $ 47 billion and $ 60 billion per year. - More than HIV, cancer diseases and combined heart
"Identifying patients at risk pre-existing pain usually those who have mental health problems , chronic opioid use before surgery, it is essential for us to develop monitoring plans and to educate patients and other health care providers, '' said Dr. Clarke. "We need to give patients the tools to manage their pain, if it becomes problematic."
The study also examined the needs of 0 patients who underwent major surgery, such as thoracic, cardiac, gynecological and head and neck, TGH in 2013-2014. The study found that 27 percent of pain patients three months after surgery were still using opioids, higher than previous estimates, which range from one to 10 percent.
These patients on opioid rated their health to be lower compared to non-opioid users, inability reports related to significant pain compared to mobility, mood and ability to work.
the pain transition service TGH was established in 2014 to meet the needs of at-risk patients, like those in this study. The service is designed to treat patients with complex pain who have undergone surgery by helping to control pain, monitoring and weaning patients off excessive amounts of opioid pain medications, and provide the necessary support primary care physicians and patients after discharge from the hospital. The objective is to improve opiates practices in hospitals to improve patient care and safety, including the identification and monitoring of risk patients before and after prescribing opioids.
The follow-up care is provided by a diverse team of clinical specialists in pain control. They use a variety of methods to help and teach patients to manage their pain, including mindfulness, "exercise prescriptions" and acupuncture.

TSRI has granted $ 20 million for the first year of Precision Medicine Initiative cohort program

TSRI has granted $ 20 million for the first year of Precision Medicine Initiative cohort program -
In the most ambitious medical research program in the history of American medicine, the Scripps Research Institute (TSRI) has received an initial price of $ 20 million for his role in a national precision medicine initiative, the national Institutes of Health (NIH) announced today.
"We are delighted to have the opportunity to help lead away -reaching, transformation program of one million or more participants in the US with long-term follow-up," said the principal investigator of the new grant Eric Topol, MD, director of the Scripps Translational science Institute (STSI), genomics professor at TSRI and academic director at Scripps Health. "Our goal at STSI for the decade of its existence was to advance personalized medicine. Using genomics, mobile applications and biosensors and provide data back to each participant, this study will establish the new medical knowledge bases and ways of engaging people looking as citizens-scientists. "
" This grant, which will total nearly $ 0 million over five years, is one of the largest federal grant ever awarded to the IRST, "said CEO Peter TSRI Schultz, PhD, "and it is the role of leader in expansion that Eric and IRST will play in this new era of biomedical research."
the five-year award is part of the cohort program the precision medicine Initiative President Obama (PMI) PMI is the Cohort Program historic longitudinal research effort that aims to engage one million or more participants in the United States to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics.
"STSI has already played a central role in a digital medical revolution that is radically changing the way we think and to provide health care, "said Chris Van Gorder, president and CEO of Scripps health, which operates in partnership with TSRI STSI. "This grant ensures the continuation of this work for the coming years on a scale that will benefit the entire nation."
The new grant will support a participant by STSI Technology Centre will play a key role in the registration of participants in the study, as well as provide mobile applications. In parallel, the center will develop platforms to provide these same functions to those without smartphones and work with organizations of technology to increase accessibility smartphones.
STSI has partnered with the Health vibrate Fairfax, Virginia, funded by NIH, which will provide the technological platform to register and engage participants through mobile applications, web application, interactive voice response, feature phones and portable sensors; Health vibrate develop, test, maintain and upgrade the technology platform to register, consent, collect data from, communicate with and engage participants throughout the grant period.
In addition, Sage Bionetworks based in Seattle, a full partner in the design, development and hosting data for a large number of mobile app-based research studies on the platform open source Apple ResearchKit, will be responsible for developing symptoms of phone measures, laptop and other sensors, as well as community outreach and engagement efforts with participants attending Technologies Center.
initiative also includes an extensive network of high-level partners, including Walgreens and PatientsLikeMe. Work in collaboration with other entities, the participant Scripps Technologies Center will be responsible for the registration of at least 350,000 participants-volunteers.
"These partners provide awareness and unprecedented commitment, and data privacy and security capabilities," Topol said.
team aims to begin the initial entry into the study this year in order to reach its membership goal by 2020.
the participants will be asked to answer questions about the history of their health and share their genomic biological information and others by simple blood tests and urine and grant access to their clinical data from records electronic health. Furthermore, devices and mobile health applications provide lifestyle data and environmental exposures in real time. All this will be accomplished with guarantees of confidentiality and security essential. As partners in research, participants will have the current input in the design and implementation study, as well as access to a wide range of their individual results and aggregated study.
"This range of information on the scale of a million people from all walks of life will be an unparalleled resource for researchers working to understand all the factors that influence health and disease, "said Director Francis S. Collins NIH, MD, Ph.D." over time, the data provided by participants will help us answer important health issues, such as why some people with genetic risk factors and high environmental for diseases still manage to maintain good health, and how people with chronic disease can maintain the highest possible quality of life. The more we understand individual differences, the better we will be able to prevent and treat the disease effectively. "
The knowledge gained in the PMI cohort program will extend the success of the precision medicine in some cancers in many other diseases. Importantly, the program will focus not only on the disease, but also on ways to increase the chances of staying healthy throughout the life of an individual
for more information on medicine precision Initiative (PMI), see https: // www. .whitehouse.gov / precision medicine. for more information on the cohort program PMI, see https://www.nih.gov/precision-medicine-initiative-cohort-program. for more information about NIH and its programs, visit www.nih.gov.
About the Scripps research Institute
the Scripps research Institute (TSRI) is one of the largest non-profit independent global research-driven in the biomedical sciences. TSRI is internationally recognized for his contributions to science and health, including its role in the foundation of new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its famous scientists, including two Nobel prize winners and 20 members of the national Academy of sciences, engineering or medicine work toward their next discoveries. The graduate program of the institute, which doctorate degrees in biology and chemistry prices, ranks among the top ten of its kind in the country. For more information, see www.scripps.edu.
Once the public, and other news releases are posted on the website of the IRST to http://www.scripps.edu/news/newsreleases.html
about Scripps health
Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps health is a nonprofit integrated health system based in San Diego, California. Scripps Health treats more than 0,000 patients annually through the commitment of 3,000 affiliated physicians and 15,000 employees among most of its five acute care hospital campuses, palliative care and home health care services, 28 centers and outpatient clinics, and hundreds of doctors offices throughout the region.
Recognized as the leader in the prevention, diagnosis and treatment, Scripps Health is also at the forefront of clinical research, genomic medicine and wireless healthcare. With three highly respected graduate medical training programs, Scripps Health is a longstanding member of the Association of American Medical Colleges. Scripps Health has been listed four times as one of the nation's top health care systems by Truven Health Analytics. Its hospitals are consistently ranked by US News & World Report among the best in the country and Scripps Health is consistently recognized by Fortune, Working Mother magazine and AARP as one of the best places in the country to work. More information can be found at www.scripps.org.
About Scripps Translational Science Institute
The Scripps Translational Science Institute aims to replace the traditional one size fits all medicines with healthcare individualized by leveraging the power of genomic medicine, wireless health sensors and mobile applications, and other digital medical technologies. In a unique collaboration, STSI merges biomedical expertise of Scripps Research Institute exceptional patient care with Scripps Health and clinical research capacity. STSI is supported in part by National Institutes of Health Clinical and Translational Science Award. For more information, visit www.stsiweb.org site.

Moffitt researchers discover new way to control the SETDB1 protein upregulated in cancer

Moffitt researchers discover new way to control the SETDB1 protein upregulated in cancer -
Cancer is a group of more than 100 different diseases. All are driven by the cells and genes that are beyond the normal process of division and begin their own plan to replicate in the body. Advances in genetics and molecular biology offer researchers a better understanding of genetic mutations and cell changes that can lead to cancer, and also how to use this information to develop measures and preventive therapies to target diseases.
Moffitt Cancer Center, a leader in molecular cancer research, and a research team led by Jia Fang, Ph.D., assistant member of the department of biology of the tumor, discovered a new how to control the activity of SETDB1, a protein that is often upregulated in cancer. Their results were published in the June issue 16 Molecular Cell .
The new mechanism to control protein function is called monoubiquitination. The proteins can be resolved through a process called ubiquitination, in which a ubiquitin molecule is added to a protein. modification of ubiquitin may give rise to a number of different effects. The addition of a large number of ubiquitin molecules can target a protein degradation, whereas the addition of a single ubiquitin molecule (to monoubiquitination) can lead to activation of signaling pathways proteins or other target protein for the ubiquitination. Ubiquitin is generally added to a protein by an orderly series of events - activation by an E1 enzyme, by conjugation E2 enzyme and ligation with a E3 enzyme
SETDB1 regulates the level of compaction of the DNA and gene expression .. SETDB1 When activated, the levels of target gene expression is repressed. Given its essential role in the control of gene expression, SETDB1 must be set precisely so that the molecular processes are working properly.
Moffitt researchers carried out molecular studies demonstrate for the first time that constitutively SETDB1 is modified by a single ubiquitin molecule. Event ubiquitination is mediated by enzymes E1 and E2, without the traditional participation of an E3 enzyme. Importantly, this monoubiquitination serves as an integral part of SETDB1 to make its activity and leads to inhibition of expression of the target gene.
"This is the first demonstration that a constituent monoubiquitination by complete E2 enzyme the function of a key enzyme. These results suggest that this enzyme E2 class is an attractive target for cancer therapeutics" said Fang.

Women who undergo axillary lymph node surgery for cancer more likely to develop chronic pain in

Women who undergo axillary lymph node surgery for cancer more likely to develop chronic pain in -
An analysis conducted by researchers from McMaster University found that women who undergo surgery lymph nodes in the armpit breast cancer are much more likely to develop chronic pain.
CMAJ today released its review of studies investigating the risk factors for the development of chronic pain after breast cancer surgery that also included younger age and radiotherapy.
"ten-year survival rates for patients with breast cancer are now around 83%, but up to 60% of women who undergo surgery as part of cancer treatment, can develop chronic pain, "said lead author Jason Busse. He is an assistant professor of anesthesia, and a researcher at the Institute G. DeGroote Michael for research and treatment of pain in Michael G. DeGroote School of Medicine.
the international research team, led by postdoctoral student Dr. Busse, Dr. Wang Li, conducted a systematic review which analyzed 30 observational studies which enrolled 20,000 women undergoing surgery for breast cancer. the analysis of these data suggests that disruption of the sensory nerves in the axilla (underarm) lymph nodes are removed is associated with the development of chronic pain.
" We can not be certain that efforts to save the nerves during axillary surgery for breast cancer will prevent the development of chronic pain, "said Busse. "Although we found a 21% increase in the risk of chronic post-surgical pain associated with surgery axillary nodes, sparing nerve may not always be possible, and if possible can not reduce the risk of chronic pain as much as current evidence suggests. "
changes are made in the world to change treatment, said Dr. Susan Reid, author of the study. She is also professor and chair of surgery at the Michael G. DeGroote School of Medicine at McMaster University and a breast cancer surgeon.
"The current standards in axillary surgery have already undergone a significant change to sentinel node biopsy, which reduces the potential complications for many patients," she said.

Researchers are developing a new hybrid method for studying the HIV protein involved in the progression of the disease

Researchers are developing a new hybrid method for studying the HIV protein involved in the progression of the disease -

More than 36 million people worldwide, including 1.2 million in the United States living with HIV. antiretroviral cocktails block today how HIV replicates, matures and enters the uninfected cells, but they can not eradicate the virus.

Mike Kent, researcher in bioengineering and Sandia National Laboratories Science Centre, is studying a protein called Nef implicated in the progression from HIV to AIDS with the ultimate goal of the block. He and his collaborators have developed a new hybrid method for studying the HIV protein that compromises the immune system. The method could also work on many other proteins that damage cellular processes and cause disease.

Nef goes to the membrane of the infected cell and tricks the cell into destroying its own signaling system immune receptors, allowing the infected cell to evade the immune system. Nef also diverts cellular communications to make it easier for the virus to reproduce. To interact with host proteins, Nef needs to change shape.

This shape-shifting protein is so important that rhesus monkeys infected with a version of simian immunodeficiency virus closely related that lacks the protein Nef don 't develop symptoms of immune deficiency.

"Nef is an essential protein for AIDS. It accomplishes its tasks by modifying the signaling and receptor trafficking. It binds to receptors of the immune system critical and then signals your cells to destroy them. If you how this protein works, you have a better chance to develop drugs to stop it, "said Kent.

combining both techniques reveals the Nave structure and function

Kent and chemistry professor John Engen bioanalytical team at Northeastern University has combined two biophysical techniques known to find out how Nef alters the structure to perform its functions.

Kent is an expert in neutron reflectometry, a technique that gets the nanoscale structural information on films and biological membranes. his team used this technique to compare the Nave overall structure in form membrane bound from its inactive form, without membrane.

strong point Engen is hydrogen-deuterium exchange mass spectrometry, a technique that measures the local structure and protein flexibility. The team used to obtain information on the local structure and dynamics of Nef when bound to the membrane.

The comprehensive information of the neutron reflectometry shows that the average position of the Nave from the membrane. The local dynamics of hydrogen-deuterium exchange mass spectrometry vest for many small parts of the protein, showing the flexibility of 30 overlapping sections, which collectively cover 0 percent of Nef. Together they build a more complete picture of the Nave and structural changes.

The global and local information specific peptide supported a widespread assumption that, in binding to the membrane, Nef modifies its structure to interact with signaling receptors and other host proteins : .. a hypothesis unsupported, so far

"people have long studied Nef and there was a model of what the people thought that the protein might look like and could be a difficult protein NEF to study because you can crystallize the folded portion of the protein, and about half of the protein is unstructured. in addition, you can not study the membrane bound form crystallography, "said Kent.

"It is the first time anyone had measured these types of structural changes and the results were consistent with the hypothetical model," added Kent. "The details of these shape changes provide important new molecular knowledge of how NEF functions." This method could lead to new drug screening tests.

To combine the two techniques, the first team needed to make a special device. It should contain a lipid monolayer flat, saturated fat, which mimicked the biological membrane. It also had to be integrated with equipment for neutron sources for measuring the reflection of neutrons, and allowing the rapid exchange of the liquid carrier layer for the experiments hydrogen-deuterium exchange.

Another challenge was successfully produced the Nef protein. In infected cells, Nef is marked with a special lipid that serves to anchor Nef to the cell membrane. Engen's team had to produce Nef which contained this vital lipid, known as a group of myristate.

This work was supported by National Institutes of Health. Neutron reflection measurements were performed neutron research center at the National Institute of Standards and Technology and the Spallation Neutron Source at Oak Ridge National Laboratory.

New method could answer many questions about HIV, other. diseases

With the hybrid method and a unique camera in hand, the team is seeking funds to answer additional questions about Nef

"We studied alone, now we want explore with its binding partners, with host proteins and complexes that form in the presence of drug molecules or inhibitors, "said Kent. "Stop bind with partners or inhibiting to adopt the conformation that leads to the degradation of the receptor have important medical implications."

Tom Smithgall of the University of Pittsburgh School of Medicine, a co-author on a paper of the team, is currently the selection of potential drugs that could block the actions of Nef

Kent also hopes to apply this hybrid method to other important structural problems of proteins associated with the membrane, including virus maturation. the fusion of the virus with the membrane of the host cell; the functioning of bacterial toxins such as botulinum, tetanus and diphtheria; and dysfunctions ranging from cancer to the regulation of signaling cells cholesterol.

"There is a lot of potential for the combination of these two techniques in a more general sense. There is no other way to get this kind of specific, direct information on membrane proteins essential. This is an important segment of biological problems that could not be tackled in our work, and we made some big steps forward. future earnings depends on the general, we can apply the method beyond celui- HIV proteins, "said Kent.

New mathematical model can help predict breast cancer growth, the appearance of metastases

New mathematical model can help predict breast cancer growth, the appearance of metastases -
Double Attack on breast cancer
personalized medicine is an approach to health care in which medical procedures are tailored to the genetic, physiological of each patient, and the biochemical type, and other characteristics. Cancer treatment is a type of care that a personal approach is needed most often applied.
Some classical mathematical models were developed to describe the natural way of breast cancer, but they tend to treat the primary tumor and "combined mathematical model of breast cancer growth" secondary metastatic growth separately according to the paper http: // .. itas2015 IITP ru / pdf / 1570162553. pdf by senior Research Fellow HSE International Laboratory for intelligent systems and analysis Alexey Neznanov structural and research assistant Laboratory Ella Tyuryumina
But the natural history of cancer does not always end with the primary tumor removal. in many cases, secondary distant metastases can then develop and, if allowed to grow to a certain size, are likely to cause death. in addition to the comprehensive treatment of the primary tumor, cancer patients are now assessed for secondary metastatic growth. The mathematical models used to facilitate such evaluation should be able to describe the steps accurately:
  • latency period of growth of the primary tumor;
  • visible primary tumor, its diagnosis and removal;
  • latency remote metastatic growth; and
  • visible secondary metastases, diagnosis and treatment, and patient outcomes, including death.
The authors' goal was to design a comprehensive mathematical model capable of describing the all natural breast cancer history, including the development of primary tumors and secondary metastases by histological stage and predict patient outcomes and survival in the processing of the primary tumor and removal.
calculation of the Invisible
by developing a new mathematical model Neznanov Tyuryumina and aimed to improve the prediction of cancer growth. In particular they aim to:
  • examination known mathematical models to describe the growth of the primary tumor and secondary metastases in breast cancer;
  • develop a comprehensive mathematical model of primary and secondary tumors develop metastases for this type of cancer (combined model);
  • identify critical periods in the context of the primary tumor and the development of secondary metastases, which can affect the survival prognosis;
  • to implement the combined model as a software solution; and
  • to determine the scope of applicability and areas of the combined model for other research.
After reviewing the available literature on the modeling of breast cancer published between 1930 and 2014, the HSE proposed a new mathematical model of exponential growth on the basis of a set of linear and deterministic non-linear equations.
Their combined model describes both primary tumor growth and metastasis by side histological stages and helps predict survival prognosis. "Right corresponding to the official classification of breast cancer, we found our model to be quite accurate in correlating the size of the primary tumor with patient survival prognosis," says Neznanov. "As already known, the removal of the primary tumor is often followed by the latent growth of secondary metastases, our model clearly shows how the rate of five-year survival depends on the size of the primary tumor in patients breast cancer. " In particular, the model can give an indication of when the metastatic cells are likely to occur, depending on the size of the primary tumor.
In order to facilitate the practical application of this combined model, a software tool has been developed which should also be used in other research - for example, allowing simple addition of new parameters for prediction more accurate survival prognosis patients. The software is integrated with a source database and the prediction results. Just two steps from the primary tumor is needed as the minimum basic data for the model.
The model and software implementing it can improve the accuracy of prediction of breast cancer development and patient outcomes, which in turn can help detect secondary metastases.
Tested a relatively small amount of clinical data, the new model showed better performance than existing tools. First results of the study were presented at the conference "Information Technologies and 2015 systems." However, according Tyuryumina, this is only the first step. The researchers now plan to test the combined model of the large amounts of clinical data, consult cancer specialists to further improve its applicability, and integrate the software with other clinical data analysis tools used in oncology.